Boston Sci reportedly looking to sell snake antivenom business

By Chris Newmarker | July 14, 2020

Boston Scientific snake antivenom rattlesnake

Boston Scientific (NYSE:BSX) is exploring selling its snake antivenom products business, according to Bloomberg, which cited anonymous sources.

A Boston Sci spokesperson told MassDevice via email that the company has a practice of not commenting on speculation.

Boston Scientific acquired the antivenom business during its $4 billion acquisition of BTG, which closed last year. Its products include CroFab, touted as the only FDA-approved product exclusively derived from U.S. snakes. CroFab to date has treated more than 50,000 people suffering from bits from snakes including rattlesnakes, copperheads and cottonmouths/water moccasins.

The BTG acquisition also included devices for vascular and oncology applications, as well as drugs for treating overdoses.

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].